Boston Scientific stock forecast
Boston Scientific's probability-weighted price is $78.68 by October 2029, with the base case carrying 54% probability. It hinges on earnings recovery, franchise defense, Penumbra integration and cash generation after the operating disruption.
Where could Boston Scientific's shares be by 2029?
The forecast points to substantial upside, but with a wide range of outcomes. The probability-weighted price is $53.78 in October 2027, implying a 21% total return. It reaches $64.69 in October 2028, implying 46%. By October 2029, the weighted price is $78.68, implying 77%.
The final-date range runs from $32.63 in the bear case to $135.23 in the bull case. Today’s price is $44.39. The forecast assigns 27% to the bear case, 54% to the base case and 19% to the bull case, so the central judgment is gradual recovery rather than either collapse or rapid reacceleration.
| Case | Probability | October 2027 | October 2028 | October 2029 |
|---|---|---|---|---|
| Bear | 27 % | 37.70 (-15 %) | 33.79 (-24 %) | 32.63 (-26 %) |
| Base | 54 % | 55.12 (+24 %) | 67.27 (+52 %) | 81.80 (+84 %) |
| Bull | 19 % | 72.83 (+64 %) | 101.27 (+128 %) | 135.23 (+205 %) |
| Weighted | 100 % | 53.78 (+21 %) | 64.69 (+46 %) | 78.68 (+77 %) |
What this means. The weighted row is the probability-based average of the three cases, not a promise that the shares will actually reach that price.
What has to go right for Boston Scientific, and what could go wrong?
The drivers are outage-related sales recovery, normalized orders, cash generation, Penumbra closing and financing, physician adoption and repeat use of FARAWAVE Ultra and ICE imaging—ultrasound pictures made from inside the heart. On October 28, 2026, the new outlook must clarify recovery and cash generation. By year-end 2026, Penumbra’s closing and financing will test integration. In the second half of 2027, FARAWAVE Ultra and ICE imaging must translate into adoption. Through 2029, restructuring cash costs and savings will test efficiency gains.
How much cash does Boston Scientific really make?
A stricter owner measure also subtracts stock-based compensation. The expense is not a current cash payment, but employees receive shares, which can dilute existing owners. Cash can fund acquisitions, debt repayment and other investment, yet it still does not prove that a new device has won clinical acceptance.
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | 4,534 | 3,435 | 2,503 | 1,526 | 1,870 |
| − Capital spending | 876 | 790 | 711 | 588 | 554 |
| = Free cash flow | 3,658 | 2,645 | 1,792 | 938 | 1,316 |
| − Stock pay | 299 | 266 | 233 | 220 | 194 |
| = Real free cash flow | 3,359 | 2,379 | 1,559 | 718 | 1,122 |
What does an investor pay for Boston Scientific today?
The price-to-earnings ratio, or P/E, tells us how much investors pay for each dollar of profit. Boston Scientific reported 2025 GAAP diluted EPS of $1.94 and adjusted EPS of $3.06. GAAP is the standardized accounting result; adjusted EPS removes selected costs such as amortization and acquisition charges. The forward P/E therefore looks lower because it assumes earnings will rise, but that comparison works only when both ratios use the same definition of profit. On the table’s figures, the implied earnings step-up is about 37%.
| Today (Oct 17, 2026) | |
|---|---|
| Share price | 44.39 |
| Market value (calculated) | 64,331.30 |
| Enterprise value (calculated) | 76,416.30 |
| P/E, last 12 months (calculated) | 18.0x |
| P/E, next 12 months (calculated) | 13.1x |
| Real free cash flow yield (calculated) | 5.2% |
What this means. Enterprise value is higher than the stock market value because it includes the company's debt after subtracting its cash.